What China’s New CGT Rules Mean for Biotech Business

Why It Matters

The new pathway reduces regulatory uncertainty and shortens time‑to‑market for individualized CGTs, making China a more attractive yet complex market for biotech partnerships and licensing.

Key Takeaways

• Order 818 creates hospital‑based commercial route for non‑drug CGTs.
• Dual‑track system lets firms choose NMPA or NHC pathway per product.
• Qualified hospitals become central hubs for manufacturing, GMP, and delivery.
• Foreign firms face sponsor‑domicile rules, impacting partnership structures.

Pulse Analysis

China has emerged as a powerhouse for cell and gene therapy research, yet the absence of a clear commercialization route has forced many innovators to license their assets abroad or operate in a regulatory gray zone. The State Council’s Order No. 818, which took effect on May 1 2026, fills that gap by authorizing qualified hospitals under the National Health Commission to conduct clinical translation and charge patients once a therapy is approved for use. By separating highly personalized products from the conventional NMPA drug‑approval pipeline, the order promises faster access to market while tightening oversight of unproven clinics.

The dual‑track framework reshapes how Chinese biotech firms structure their pipelines. Standardizable CGTs will still pursue the five‑to‑eight‑year NMPA route, but individualized therapies can now be developed in hospital‑linked GMP‑CDMO clusters that are sprouting in Chengdu, Shanghai and Hainan. This hospital‑adjacent model reduces the logistical lag between cell manufacturing and infusion, a critical factor for products with short viability windows. Consequently, domestic companies may retain more value domestically, delaying or even avoiding early out‑licensing deals that have dominated the market in recent years.

For multinational players, Order 818 is both an opportunity and a hurdle. The sponsor‑domicile requirement means foreign investors must partner with Chinese‑registered entities or set up joint ventures, and the still‑evolving Negative List limits direct involvement in stem‑cell and gene‑editing work outside designated pilot zones. At the same time, a more predictable regulatory environment could make China a larger source of real‑world data and a testing ground for next‑generation CGTs. If the hospital pathway delivers on its promise of speed and transparency, China could solidify its role as a global hub for advanced‑therapy commercialization.